Moderna Shares Fall 18% After Cutting Annual R&D Spending by $1.1 Billion From 2027
Express News | Moderna : Piper Sandler Cuts Target Price to $115 From $157
Moderna's skin cancer vaccine mRNA-4157 is expected to enter the market as early as 2025.
According to reports, moderna is planning to launch a mRNA-based skin cancer vaccine, mRNA-4157, as early as next year. The vaccine will be used in combination with merck's PD-1 therapy Keytruda for the treatment of melanoma.
S&P 500, Nasdaq Jump For 4th Straight Day As Tech Leads Stocks Higher
CSL Competitor Moderna Shifts Flu Vaccine Strategy -- Market Talk
BofA Securities Initiates Moderna(MRNA.US) With Hold Rating, Announces Target Price $110
Top Gap Ups and Downs on Thursday: SNY, DEO, GOLD and More
S&P 500 Gains and Losses Today: Moderna Stock Plunges as Firm Plans R&D Cuts
Jefferies Maintains Moderna(MRNA.US) With Buy Rating, Maintains Target Price $120
Moderna Options Spot-On: On September 12th, 189.83K Contracts Were Traded, With 447.98K Open Interest
Wall Street Today | Market Climbs, S&P 500 Within 100 Points of ATH Again
Sector Update: Health Care Stocks Rise in Thursday Trading
Trending: Moderna to Slow Down Pace of R&D Investment
Equities Rise Intraday as Traders Analyze Macro Data
Nasdaq Gains, Moderna Stock Dives -- WSJ
Moderna Cites 2025 Launch for Merck Partnered Cancer Vaccine: Report
Why Are Novavax Shares Trading Lower Today?
Sector Update: Health Care
Stocks Edge Up As Producer Inflation Supports Rate Cut Bets, Small Caps, Miners Rally: What's Driving Markets Thursday?
Moovin Stonks | Oil, Silver, Market Climbs after PPI Rises